Covered recipient · General Payments record
ARIELLE L HEEKE
Allopathic & Osteopathic Physicians Internal Medicine Hematology
General Payments · PY2018–2024
$73,672.30
- Reported across 67 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,487.50 | 8 |
| Honoraria | $1,750.00 | 1 |
| Food and Beverage | $539.08 | 5 |
| Grant | $250.00 | 1 |
| Travel and Lodging | $38.51 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech USA, Inc. | $10,395.09 | 6 |
| Acerta Pharma LLC | $4,287.50 | 3 |
| Daiichi Sankyo Inc. | $3,587.81 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,044.69 | 2 |
| PFIZER INC. | $1,750.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $250.00 | 01/30/2024 | Grant | Undisputed | 01/23/2026 | 1104712169 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,397.50 | 10/23/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105775446 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,640.00 | 11/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105574068 | CMS |
| Daiichi Sankyo Inc. | $162.81 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089432438 | CMS |
| Daiichi Sankyo Inc. | $2,055.00 | 06/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089432436 | CMS |
| Daiichi Sankyo Inc. | $685.00 | 07/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089432432 | CMS |
| Daiichi Sankyo Inc. | $685.00 | 07/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089432434 | CMS |
| Genentech USA, Inc. | $284.00 | 05/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132978686 | CMS |
| Genentech USA, Inc. | $3,125.00 | 05/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132978691 | CMS |
| Genentech USA, Inc. | $38.51 | 09/10/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1132978678 | CMS |
| Genentech USA, Inc. | $32.50 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132978682 | CMS |
| Genentech USA, Inc. | $40.08 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132978695 | CMS |
| Genentech USA, Inc. | $6,875.00 | 10/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132978674 | CMS |
| Novartis Pharmaceuticals Corporation | $19.69 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086924585 | CMS |
| Novartis Pharmaceuticals Corporation | $2,025.00 | 02/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1086924591 | CMS |
| PFIZER INC. | $1,750.00 | 01/18/2024 | Honoraria | Undisputed | 01/23/2026 | 1131473845 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.